Marianne P. Allen

Array ( [id] => 10676630 [patent_doc_number] => 20160022775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'TREATING LYSOSOMAL STORAGE DISEASE' [patent_app_type] => utility [patent_app_number] => 14/777100 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10249 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14777100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735754 [patent_doc_number] => 20140271464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'THERAPEUTIC USE OF ANTIBODIES TO HGF' [patent_app_type] => utility [patent_app_number] => 14/212104 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 86 [patent_figures_cnt] => 86 [patent_no_of_words] => 110704 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14212104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670882 [patent_doc_number] => 20160017027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'Hybridoma Clones and Monoclonal Antibodies to Fibroblast Growth Factor 4' [patent_app_type] => utility [patent_app_number] => 14/774083 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12814 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14774083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771185 [patent_doc_number] => 20140294847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'BIOLOGICAL MATERIALS RELATED TO C-MET' [patent_app_type] => utility [patent_app_number] => 14/197402 [patent_app_country] => US [patent_app_date] => 2014-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 62525 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14197402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9719714 [patent_doc_number] => 20140255413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'Combination therapy for neoplasia treatment' [patent_app_type] => utility [patent_app_number] => 14/196231 [patent_app_country] => US [patent_app_date] => 2014-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 9954 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14196231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9560594 [patent_doc_number] => 20140178307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/192924 [patent_app_country] => US [patent_app_date] => 2014-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12208 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14192924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9561897 [patent_doc_number] => 20140179610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF' [patent_app_type] => utility [patent_app_number] => 14/186331 [patent_app_country] => US [patent_app_date] => 2014-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 24280 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14186331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9546713 [patent_doc_number] => 20140171361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'METHODS FOR TREATING METABOLIC DISORDERS USING FGF' [patent_app_type] => utility [patent_app_number] => 14/184621 [patent_app_country] => US [patent_app_date] => 2014-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 16053 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14184621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11785163 [patent_doc_number] => 09394515 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-19 [patent_title] => 'Poultry performance' [patent_app_type] => utility [patent_app_number] => 14/184002 [patent_app_country] => US [patent_app_date] => 2014-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18262 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14184002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729638 [patent_doc_number] => 20160075788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'A Novel EGFR Variant' [patent_app_type] => utility [patent_app_number] => 14/768275 [patent_app_country] => US [patent_app_date] => 2014-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9241 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14768275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9597163 [patent_doc_number] => 20140193843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER' [patent_app_type] => utility [patent_app_number] => 14/181056 [patent_app_country] => US [patent_app_date] => 2014-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10406 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14181056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11356385 [patent_doc_number] => 09533025 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Method for treating chemotherapy-induced male infertility' [patent_app_type] => utility [patent_app_number] => 14/177103 [patent_app_country] => US [patent_app_date] => 2014-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9622 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14177103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9951144 [patent_doc_number] => 08999929 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-07 [patent_title] => 'Fibroblast growth factor 1 protein fragments and methods of use' [patent_app_type] => utility [patent_app_number] => 14/176992 [patent_app_country] => US [patent_app_date] => 2014-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 50992 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14176992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700559 [patent_doc_number] => 20160046706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'ANTIBODY AGAINST HUMAN NRG1 PROTEIN' [patent_app_type] => utility [patent_app_number] => 14/765581 [patent_app_country] => US [patent_app_date] => 2014-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 21024 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14765581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10063923 [patent_doc_number] => 09102755 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-11 [patent_title] => 'Highly stabilized epidermal growth factor mutants' [patent_app_type] => utility [patent_app_number] => 14/172310 [patent_app_country] => US [patent_app_date] => 2014-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8027 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14172310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129251 [patent_doc_number] => 20160326226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'RETICULOCYTE GROWTH FACTOR AND PREPARING METHOD AND APPLICATION THEREOF' [patent_app_type] => utility [patent_app_number] => 15/036075 [patent_app_country] => US [patent_app_date] => 2014-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4322 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15036075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10968122 [patent_doc_number] => 20140371155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/163826 [patent_app_country] => US [patent_app_date] => 2014-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11349 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14163826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10468596 [patent_doc_number] => 20150353612 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2015-12-10 [patent_title] => 'NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/163755 [patent_app_country] => US [patent_app_date] => 2014-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11350 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14163755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10468596 [patent_doc_number] => 20150353612 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2015-12-10 [patent_title] => 'NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/163755 [patent_app_country] => US [patent_app_date] => 2014-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11350 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14163755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11492623 [patent_doc_number] => 20170066808 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-03-09 [patent_title] => 'Stabilized Insulin-like Growth Factor Polypeptides' [patent_app_type] => utility [patent_app_number] => 14/155974 [patent_app_country] => US [patent_app_date] => 2014-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 12651 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14155974 [rel_patent_id] =>[rel_patent_doc_number] =>)